Company Filing History:
Years Active: 2018-2024
Title: Edna Meilin: Innovator in Cancer Therapy
Introduction
Edna Meilin is a prominent inventor based in Kfar Veradim, Israel. She has made significant contributions to the field of cancer therapy through her innovative research and patented inventions. With a total of 2 patents, her work focuses on improving immunotherapies and developing methods for treating cancer.
Latest Patents
One of Edna Meilin's latest patents is titled "Methods and compositions for decreasing soluble immune receptor CD28." This invention provides methods for treating cancer and enhancing immunotherapies by decreasing soluble immune receptor levels. It includes agents that bind to the membranal immune receptor and inhibit its proteolytic cleavage, as well as agents that bind to the soluble immune receptor without acting as receptor agonists or antagonists.
Another significant patent is "Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy." This invention offers compositions that include anti-CEACAM1 antibodies and antibodies capable of blocking the interaction between PD-1 and its ligands. The methods outlined in this patent aim to combine these agents for effective cancer treatment.
Career Highlights
Throughout her career, Edna Meilin has worked with notable companies such as Ccam Biotherapeutics Ltd. and Biond Biologics Ltd. Her experience in these organizations has contributed to her expertise in biotherapeutics and cancer research.
Collaborations
Edna has collaborated with several professionals in her field, including Yair Sapir and Tehila Ben-Moshe. These collaborations have further enhanced her research and development efforts in cancer therapies.
Conclusion
Edna Meilin is a dedicated inventor whose work in cancer therapy has the potential to make a significant impact on treatment options. Her innovative patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.